Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults
- PMID: 3521480
- PMCID: PMC176405
- DOI: 10.1128/AAC.29.2.339
Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults
Abstract
In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical